Robert W. Baird Boosts Neurogene (NASDAQ:NGNE) Price Target to $72.00

Neurogene (NASDAQ:NGNE) had its price target upped by Robert W. Baird from $54.00 to $72.00 in a report issued on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, HC Wainwright cut their price objective on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Neurogene has a consensus rating of “Buy” and a consensus target price of $63.33.

Neurogene Stock Down 12.0 %

NASDAQ:NGNE opened at $34.52 on Tuesday. Neurogene has a 1 year low of $12.49 and a 1 year high of $74.49. The stock has a 50-day simple moving average of $47.11 and a 200-day simple moving average of $40.11.

Institutional Trading of Neurogene

A number of large investors have recently bought and sold shares of the business. RTW Investments LP lifted its position in Neurogene by 6.0% during the 3rd quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock worth $47,635,000 after acquiring an additional 64,691 shares during the period. FMR LLC lifted its holdings in shares of Neurogene by 912.4% during the third quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after purchasing an additional 659,515 shares during the period. Vanguard Group Inc. grew its position in Neurogene by 906.5% in the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after buying an additional 457,062 shares during the last quarter. Baker BROS. Advisors LP increased its stake in Neurogene by 0.6% in the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after buying an additional 2,499 shares during the period. Finally, State Street Corp raised its position in Neurogene by 17.5% during the 3rd quarter. State Street Corp now owns 246,540 shares of the company’s stock worth $10,345,000 after buying an additional 36,687 shares during the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.